全文获取类型
收费全文 | 33231篇 |
免费 | 2104篇 |
国内免费 | 865篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 443篇 |
妇产科学 | 315篇 |
基础医学 | 1994篇 |
口腔科学 | 212篇 |
临床医学 | 2786篇 |
内科学 | 7529篇 |
皮肤病学 | 327篇 |
神经病学 | 2306篇 |
特种医学 | 492篇 |
外国民族医学 | 1篇 |
外科学 | 2183篇 |
综合类 | 3345篇 |
一般理论 | 3篇 |
预防医学 | 2322篇 |
眼科学 | 170篇 |
药学 | 9525篇 |
20篇 | |
中国医学 | 1422篇 |
肿瘤学 | 753篇 |
出版年
2023年 | 571篇 |
2022年 | 896篇 |
2021年 | 1462篇 |
2020年 | 1182篇 |
2019年 | 1502篇 |
2018年 | 1570篇 |
2017年 | 1350篇 |
2016年 | 1108篇 |
2015年 | 1147篇 |
2014年 | 2501篇 |
2013年 | 3149篇 |
2012年 | 1871篇 |
2011年 | 2072篇 |
2010年 | 1594篇 |
2009年 | 1426篇 |
2008年 | 1417篇 |
2007年 | 1305篇 |
2006年 | 1068篇 |
2005年 | 974篇 |
2004年 | 784篇 |
2003年 | 723篇 |
2002年 | 542篇 |
2001年 | 500篇 |
2000年 | 395篇 |
1999年 | 329篇 |
1998年 | 287篇 |
1997年 | 289篇 |
1996年 | 265篇 |
1995年 | 243篇 |
1994年 | 216篇 |
1993年 | 249篇 |
1992年 | 222篇 |
1991年 | 176篇 |
1990年 | 166篇 |
1989年 | 150篇 |
1988年 | 158篇 |
1987年 | 104篇 |
1986年 | 114篇 |
1985年 | 210篇 |
1984年 | 244篇 |
1983年 | 200篇 |
1982年 | 191篇 |
1981年 | 186篇 |
1980年 | 155篇 |
1979年 | 154篇 |
1978年 | 153篇 |
1977年 | 131篇 |
1976年 | 125篇 |
1975年 | 119篇 |
1974年 | 83篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
11.
《Australian critical care》2019,32(6):540-559
ObjectivesThe objective of this review was to describe cardiovascular risk (CVR) assessment methods and to identify evidence-based practice recommendations when dealing with population at risk of developing cardiovascular diseases.Review methods and data sourcesA literature review following the Arksey and O'Malley scoping review methodology was conducted. By using appropriate key terms, literature searches were conducted in PubMed, SciELO, Cochrane Library, Dialnet, ENFISPO, Medigraphic, ScienceDirect, Cuiden, and Lilacs databases. A complementary search on websites related to the area of interest was conducted. Articles published in English or Spanish in peer-review journals between 2010 and 2017. Critical appraisal for methodological quality was conducted. Data was extracted using ad-hoc tables and qualitatively synthesized.ResultsAfter eliminating duplicates, 55 325 records remained, and 1432 records were selected for screening. Out of these, 88 full-text articles were selected for eligibility criteria, and finally, 67 studies were selected for this review, and 25 studies were selected for evidence synthesis. In total, 23 CVR assessment tools have been identified, pioneered by the Framingham study. Qualitative findings were grouped into four thematic areas: assessment tools and scores, CVR indicators, comparative models, and evidence-based recommendations.ConclusionsIt is necessary to adapt the instruments to the epidemiological reality of the population. The most appropriate way to estimate CVR is to choose the assessment tool that best suits individual conditions, accompanied by a comprehensive assessment of the patient. More research is required to determine a single, adequate, and reliable tool. 相似文献
12.
Cristiano Colalto 《Drug development research》2020,81(8):950-968
COVID-19 is a novel coronavirus disease with a higher incidence of bilateral pneumonia and pleural effusion. The high pulmonary tropism and contagiousness of the virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have stimulated new approaches to combat its widespread diffusion. In developing new pharmacological strategies, the chemical characteristic of volatility can add therapeutic value to the hypothetical drug candidate. Volatile molecules are characterized by a high vapor pressure and are consequently easily exhaled by the lungs after ingestion. This feature could be exploited from a pharmacological point of view, reaching the site of action in an uncommon way but allowing for drug delivery. In this way, a hypothetical molecule for COVID-19 should have a balance between its lung exhalation characteristics and both antiviral and anti-inflammatory pharmacological action. Here, the feasibility, advantages, and disadvantages of a therapy based on oral administration of possible volatile drugs for COVID-19 will be discussed. Both aerosolized antiviral therapy and oral intake of volatile molecules are briefly reviewed, and an evaluation of 1,8-cineole is provided in view of a possible clinical use and also for asymptomatic COVID-19. 相似文献
13.
14.
15.
Daisuke Ishibashi Takeshi Ishikawa Satoshi Mizuta Hiroya Tange Takehiro Nakagaki Tsuyoshi Hamada Noriyuki Nishida 《Neurotherapeutics》2020,17(4):1836
The accumulation of abnormal prion protein (PrPSc) produced by the structure conversion of PrP (PrPC) in the brain induces prion disease. Although the conversion process of the protein is still not fully elucidated, it has been known that the intramolecular chemical bridging in the most fragile pocket of PrP, known as the “hot spot,” stabilizes the structure of PrPC and inhibits the conversion process. Using our original structure-based drug discovery algorithm, we identified the low molecular weight compounds that predicted binding to the hot spot. NPR-130 and NPR-162 strongly bound to recombinant PrP in vitro, and fragment molecular orbital (FMO) analysis indicated that the high affinity of those candidates to the PrP is largely dependent on nonpolar interactions, such as van der Waals interactions. Those NPRs showed not only significant reduction of the PrPSc levels but also remarkable decrease of the number of aggresomes in persistently prion-infected cells. Intriguingly, treatment with those candidate compounds significantly prolonged the survival period of prion-infected mice and suppressed prion disease-specific pathological damage, such as vacuole degeneration, PrPSc accumulation, microgliosis, and astrogliosis in the brain, suggesting their possible clinical use. Our results indicate that in silico drug discovery using NUDE/DEGIMA may be widely useful to identify candidate compounds that effectively stabilize the protein.Electronic supplementary materialThe online version of this article (10.1007/s13311-020-00903-9) contains supplementary material, which is available to authorized users. 相似文献
16.
17.
18.
19.